250
Participants
Start Date
November 30, 2003
Primary Completion Date
April 30, 2005
Study Completion Date
April 30, 2005
GW590735
1µg to 20µg daily doses of GW590735
fenofibrate
Marketed Drug
GSK Investigational Site, New York
GSK Investigational Site, Endwell
GSK Investigational Site, Williamsville
GSK Investigational Site, Rochester
GSK Investigational Site, Erie
GSK Investigational Site, Allentown
GSK Investigational Site, Richmond
GSK Investigational Site, Norfolk
GSK Investigational Site, Wilmington
GSK Investigational Site, Statesville
GSK Investigational Site, Jacksonville
GSK Investigational Site, Jacksonville
GSK Investigational Site, DeLand
GSK Investigational Site, Hollywood
GSK Investigational Site, Pembroke Pines
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Fort Lauderale
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, Birmingham
GSK Investigational Site, Bristol
GSK Investigational Site, Kingsport
GSK Investigational Site, Louisville
GSK Investigational Site, Cincinnati
GSK Investigational Site, Cincinnati
GSK Investigational Site, Indianapolis
GSK Investigational Site, Evansville
GSK Investigational Site, Iowa City
GSK Investigational Site, Brooklyn Center
GSK Investigational Site, Sioux Falls
GSK Investigational Site, Orland Park
GSK Investigational Site, Omaha
GSK Investigational Site, Houston
GSK Investigational Site, Conroe
GSK Investigational Site, Bryan
GSK Investigational Site, San Antonio
GSK Investigational Site, Phoenix
GSK Investigational Site, Phoenix
GSK Investigational Site, Scottsdale
GSK Investigational Site, Beverly Hills
GSK Investigational Site, Spring Valley
GSK Investigational Site, Orange
GSK Investigational Site, Walnut Creek
GSK Investigational Site, Healdsburg
GSK Investigational Site, Medford
GSK Investigational Site, Auburn
GSK Investigational Site, Calgary
GSK Investigational Site, Winnipeg
GSK Investigational Site, Laval
GSK Investigational Site, Québec
GSK Investigational Site, Sainte-Foy
Lead Sponsor
GlaxoSmithKline
INDUSTRY